Bone marrow-derived CD13+ cells sustain tumor progression: A potential non-malignant target for anticancer therapy

 
Thumbnail
View/Open
Author
Dondossola, Eleonora
Corti, Angelo
Arap, Wadih
Pasqualini, Renata
Published Version
https://doi.org/10.4161/onci.27716
Metadata
Show full item record
Citation
Dondossola, Eleonora, Angelo Corti, Richard L Sidman, Wadih Arap, and Renata Pasqualini. 2014. “Bone marrow-derived CD13+ cells sustain tumor progression: A potential non-malignant target for anticancer therapy.” Oncoimmunology 3 (1): e27716. doi:10.4161/onci.27716. http://dx.doi.org/10.4161/onci.27716.
Abstract
Non-malignant cells found within neoplastic lesions express alanyl (membrane) aminopeptidase (ANPEP, best known as CD13), and CD13-null mice exhibit limited tumor growth and angiogenesis. We have recently demonstrated that a subset of bone marrow-derived CD11b+CD13+ myeloid cells accumulate within neoplastic lesions in several murine models of transplantable cancer to promote angiogenesis. If these findings were confirmed in clinical settings, CD11b+CD13+ myeloid cells could become a non-malignant target for the development of novel anticancer regimens.
Other Sources
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4203577/pdf/
Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:13890756

Collections